Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Doing Well By Doing Good: FDA's Orphan Product Head Makes His Case to Pharma

This article was originally published in RPM Report

Executive Summary

Tim Coté has been a tireless advocate for greater involvement by Big Pharma in orphan drug research since taking over as head of FDA's Orphan Products Office two years ago. We talked to him about the response he's heard so far.

You may also be interested in...



Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.

Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets

Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.

A Rare Opportunity? NIH Program For Rare Diseases May Have Big Payoff For Drug Development

NIH Director Francis Collins is very excited about a $24 million program to de-risk small molecule treatments for rare disorders. You should be too.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS080521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel